AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36809195
Drug: Setanaxib 400
RxNorm normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setanaxib 400 mg BID (moderate-to-severe fatigue at baseline)
Trial: 36809195
Drug: Setanaxib 400
RxNorm normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setanaxib 400 mg BID (mild fatigue at baseline)
Trial: 36809247
Drug: Community-administered pre-referral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-administered pre-referral rectal artesunate (RAS)
Trial: 36809247
Drug: Parenteral antimalarial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral antimalarial and ACT administration
Trial: 36809247
Drug: ACT administration
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT administration at discharge
Trial: 36809247
Drug: Parenteral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Parenteral artesunate not followed up with oral ACT
Trial: 36809321
Drug: Aspirin discontinuation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin discontinuation (intervention group) until delivery
Trial: 36809321
Drug: Aspirin continuation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin continuation (control group) until 36 weeks of gestation
Trial: 36809852
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (30 g); TID of AAs in whey was 97% ± 2.4% in humans and 97% ± 1.9% in pigs; if free AAs absorbed, TID would increase by 0.4%-units in humans and 0.1%-units in pigs.
Trial: 36810101
Drug: Fluid balance
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid balance control strategy (daily weight-driven restriction of fluid intake, diuretics administration, ultrafiltration if renal replacement therapy)
Trial: 36810100
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of metabolic changes among biological matrices
Trial: 36810120
Drug: Modified Prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Prolonged Exposure (mPE) therapy plus Treatment as Usual (TAU)
Trial: 36810173
Drug: Antimicrobial stewardship
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial stewardship based on daily clinical assessment of clinical cure, allowing discontinuation of antibiotic therapy when at least three criteria of clinical cure are met.
Trial: 36810173
Drug: Standard management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard management with a fixed duration of appropriate antibiotic therapy for 7 days according to international guidelines.
Trial: 36810194
Drug: Ivermectin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (400 mcg/kg) administered monthly for 3 months
Trial: 36810194
Drug: Ivermectin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (400 mcg/kg) plus livestock treatment with injectable ivermectin (200 mcg/kg) monthly for 3 months
Trial: 36810194
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) monthly for 3 months
Trial: 36810788
Drug: Ustekinumab or
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab or TNF inhibitor (TNFi)
Trial: 36810939
Drug: Intranasal dexmedetomidine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine-based regimens (most common dose 3 to 3.9 mcg/kg)
Trial: 36810939
Drug: Intranasal dexmedetomidine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine-based regimens
Trial: 36810945
Drug: Low-dose glucocorticoids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glucocorticoids (≤ 7.5mg/day prednisone)
Trial: 36811311
Drug: GLP-1, OXM,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1, OXM, PYY (GOP) infusion for 4 weeks
Trial: 36811382
Drug: WNT974 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WNT974 + encorafenib + cetuximab (COMBO10: 10 mg, COMBO7.5: 7.5 mg, COMBO5: 5 mg)
Trial: 36811557
Drug: cBMA augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cBMA augmentation
Trial: 36811846
Drug: Bilastine 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilastine 0.6% ophthalmic solution
Trial: 36811937
Drug: Layperson-facilitated internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Layperson-facilitated internet-delivered cognitive behavioral therapy (Empower@Home), 10-week intervention
Trial: 36811937
Drug: Layperson-facilitated internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Layperson-facilitated internet-delivered cognitive behavioral therapy (Empower@Home)
Trial: 36811949
Drug: Guselkumab 200
RxNorm normalized name: guselkumab 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 200 mg subcutaneously every 4 weeks for 16 weeks
Trial: 36811991
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (FCM) 500 mg administered <48 hours before surgery
Trial: 36812121
Drug: Routine daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine daily physical activity (control)
Trial: 36812434
Drug: Etranacogene dezaparvovec
RxNorm normalized name: Etranacogene dezaparvovec
DrugBank: Etranacogene dezaparvovec (DB16791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etranacogene dezaparvovec gene therapy (AAV5 vector expressing Padua factor IX variant)
Trial: 39341368
Drug: Etranacogene dezaparvovec
RxNorm normalized name: Etranacogene dezaparvovec
DrugBank: Etranacogene dezaparvovec (DB16791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etranacogene dezaparvovec gene therapy
Trial: 36812433
Drug: Valoctocogene roxaparvovec
RxNorm normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valoctocogene roxaparvovec therapy (single infusion of 6×10^13 vg/kg)
Trial: 36812433
Drug: Valoctocogene roxaparvovec
RxNorm normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valoctocogene roxaparvovec therapy
Trial: 36812616
Drug: Sensor-derived daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-derived daily activity
Trial: 36812723
Drug: AFD-specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFD-specific treatment
Trial: 36812894
Drug: Enhanced nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced nutrition protocol (early initiation of intralipids and faster advancement of glucose infusion rate)
Trial: 36813084
Drug: W-SUDs (relational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: W-SUDs (relational agent)
Trial: 36813086
Drug: Electronic peer
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic peer navigation (peer support via phone and automated monthly text messages)
Trial: 36813284
Drug: Multifaceted antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted antibiotic stewardship intervention
Trial: 36813496
Drug: TCP-25 gel
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCP-25 gel (topical application on suction blister wounds)
Trial: 36813496
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (topical application on suction blister wounds)
Trial: 36813503
Drug: Inhaled ciclesonide
RxNorm normalized name: ciclesonide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ciclesonide 320 µg two times a day for 14 days
Trial: 36813504
Drug: Lidocaine hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine hydrochloride 5 mg/g ear drops (Otalgan) one to two drops up to six times daily for a maximum of 7 days in addition to usual care (oral analgesics, with/without antibiotics)
Trial: 36813504
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (oral analgesics, with/without antibiotics)
Trial: 36813747
Drug: SH-1028 200
RxNorm normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SH-1028 200 mg once daily
Trial: 36813747
Drug: SH-1028 240
RxNorm normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SH-1028 240 mg cohort
Trial: 36813747
Drug: SH-1028 300
RxNorm normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SH-1028 300 mg cohort
Trial: 36813867
Drug: Concomitant nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concomitant nab-paclitaxel + gemcitabine chemotherapy
Trial: 36813867
Drug: Sequential nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential nab-paclitaxel + gemcitabine chemotherapy
Trial: 36814246
Drug: Targeted therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapies (13 EMA-approved drugs)
Trial: 36814898
Drug: Serclutamab talirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serclutamab talirine (Ser-T) monotherapy at doses up to 50 μg/kg, followed by 25 μg/kg Q4W
Trial: 36814898
Drug: Serclutamab talirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serclutamab talirine (Ser-T) at recommended phase II dose (RP2D)
Trial: 37709999
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with therapy
Trial: 36815261
Drug: Mental health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental health Narrative Community-Based Group Therapy (NCGT)
Trial: 36815322
Drug: 3HP therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3HP therapy (weekly rifapentine plus isoniazid)
Trial: 36816341
Drug: Polypill therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill therapy (combination of ≥2 blood pressure medications and a statin with or without aspirin)
Trial: 36816343
Drug: Icotinib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib (125 mg, three times daily for 12 months)
Trial: 36816342
Drug: Vixarelimab 360
RxNorm normalized name: Vixarelimab
DrugBank: Vixarelimab (DB16350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vixarelimab 360 mg weekly (720 mg loading dose)
Trial: 36816574
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (SBP goals of 110-130 mmHg)
Trial: 36816574
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SBP goals of 130-150 mmHg)
Trial: 36816939
Drug: Long-course chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course chemoradiotherapy combined with concurrent tislelizumab (50 Gy/25 f, 2 Gy/f, 5 days/week; capecitabine 1000 mg/m2 bid, day 1-14 for three 21-day cycles; tislelizumab 200 mg, day 8 for three 21-day cycles)
Trial: 36816939
Drug: Long-course chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course chemoradiotherapy combined with concurrent tislelizumab
Trial: 36817467
Drug: GAD-alum administered
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum administered into lymph nodes
Trial: 36817467
Drug: GAD-alum injections
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum injections
Trial: 36817762
Drug: Occupational Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational Therapy (OT) intervention twice a day plus standard non-pharmacological prevention measures for 5 days after surgery
Trial: 36817782
Drug: Procalcitonin-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin-guided treatment (PCT)
Trial: 36818595
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of mRNA vaccine
Trial: 36818595
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of mRNA vaccine
Trial: 36819685
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement + placebo (SU-PL)
Trial: 36819685
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement + probiotics (SU-PR)
Trial: 36820098
Drug: BGB-DXP593 5
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGB-DXP593 5 mg/kg
Trial: 36820098
Drug: BGB-DXP593 15
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGB-DXP593 15 mg/kg
Trial: 36820098
Drug: BGB-DXP593 30
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGB-DXP593 30 mg/kg
Trial: 36821768
Drug: Axicabtagene ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axicabtagene ciloleucel (axi-cel) autologous anti-CD19 CAR T-cell therapy (2 × 10^6 cells per kg)
Trial: 36821768
Drug: Axicabtagene ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axicabtagene ciloleucel (axi-cel) autologous anti-CD19 CAR T-cell therapy
Trial: 36822031
Drug: Telephone delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone delivered problem-solving treatment
Trial: 36822079
Drug: Pecan-enriched diet
RxNorm normalized name: Pecan
DrugBank: Pecan (DB10555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pecan-enriched diet (68 g of pecans/d)
Trial: 36822161
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus camrelizumab therapy
Trial: 36822255
Drug: Intravenous Shenfu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Shenfu injection (80mL Shenfu injection + 70mL 5% glucose injection)
Trial: 36822255
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (150mL 5% glucose injection)
Trial: 36822256
Drug: Adjunctive relining
RxNorm normalized name: LidoPro Pain Relieving Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive relining stents
Trial: 36822371
Drug: Vibrating capsule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibrating capsule, once daily, 5 days a week for 8 weeks
Trial: 36822371
Drug: Placebo, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily, 5 days a week for 8 weeks
Trial: 36822634
Drug: Ecleralimab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecleralimab (4 mg once-daily inhaled)
Trial: 36822667
Drug: Durvalumab (durva)
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (durva) with radiation therapy (RT) for 7 weeks followed by adjuvant durvalumab for 1 year
Trial: 36822667
Drug: Durvalumab (durva)
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (durva) with radiation therapy (RT) for 7 weeks
Trial: 36822839
Drug: GSK3640254 (GSK'254)
RxNorm normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 (GSK'254) 200 mg once daily from Days 11 to 20 and a single dose of cocktail + GSK'254 200 mg on Day 21
Trial: 36822839
Drug: GSK3640254 (GSK'254)
RxNorm normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 (GSK'254) 200 mg once daily
Trial: 36823150
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day orally; neoadjuvant phase for 42 days and adjuvant phase to 12 months)
Trial: 36823150
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus cisplatin (GC group; gemcitabine 1250 mg/m2, dosage not fully specified)
Trial: 36823164
Drug: Home non-invasive
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home non-invasive mechanical ventilation (HMV) with home oxygen therapy (HOT)
Trial: 36823164
Drug: Home oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home oxygen therapy (HOT) alone
Trial: 36823200
Drug: gB/MF59 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gB/MF59 vaccine candidate
Trial: 36823302
Drug: Vorasidenib 50
RxNorm normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorasidenib 50 mg once daily (q.d.)
Trial: 36823302
Drug: Ivosidenib 500
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivosidenib 500 mg once daily (q.d.)
Trial: 36823349
Drug: Dostarlimab 500
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab 500 mg every 3 weeks for four cycles, then 1000 mg every 6 weeks
Trial: 36823559
Drug: Dialogue-based webinar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialogue-based webinar intervention facilitated by a LTCW and a medical expert, guided by an evidence-based COVID-19 vaccine decision tool.
Trial: 36823559
Drug: Curated social
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curated social media web application intervention featuring interactive, dynamic content about COVID-19 and relevant vaccines.
Trial: 36823559
Drug: Enhanced usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced usual practice directing participants to online public health information about COVID-19 vaccines.
Trial: 36823645
Drug: Telehealth delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth delivery of treatments
Trial: 36823645
Drug: Assistance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assistance with scheduling of assigned treatments
Trial: 36824611
Drug: SPSPII score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPSPII score system applied before treatment
Trial: 36824884
Drug: Smartphone intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smartphone intervention for medication assisted treatment
Trial: 36825238
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eight blood biomarkers
Trial: 36826476
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg on day 1 and day 14)
Trial: 36826820
Drug: Epirubicin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (75 mg/m2) and paclitaxel (175 mg/m2) every 3 weeks for 6 cycles (EP regimen)
Trial: 36826820
Drug: Epirubicin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks for 4 cycles followed by paclitaxel (175 mg/m2) every 3 weeks for 4 cycles (EC-P regimen)
Trial: 36826834
Drug: Intensive diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive diabetes management (automated insulin delivery system)
Trial: 36826995
Drug: MEDI-570 (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-570 (monoclonal antibody against ICOS) administered intravenously every 3 weeks for up to 12 cycles at doses ranging from 0.01 to 3 mg/kg.
Trial: 36826996
Drug: Open-Source Automated
RxNorm normalized name: AMYLOPECTIN, UNSPECIFIED SOURCE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-Source Automated Insulin Delivery AndroidAPS
Trial: 36828201
Drug: Standard-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose tacrolimus (TAC) and mycophenolate mofetil (MMF)
Trial: 36828343
Drug: Normoglycemic (glycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycemic (glycemia 2.2 to 8.3 mmol/L)
Trial: 36828343
Drug: Hypoglycemic (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemic (at least 1 measurement <2.2 mmol/L)
Trial: 36828343
Drug: Hyperglycemic (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemic (at least 1 measurement >8.3 mmol/L)
Trial: 36828619
Drug: CC family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC family history
Trial: 36828643
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg at week 0, week 4, then every 8 weeks (Q8W)